glp-1 news nov 2025 November in review: breakthroughs, UPFs under fire, Novonesis advances healthy longevity Understanding GLP-1s and their dynamic

October 2023: JAMA Research Letter Warns of Possible Ozempic Risks A research letter filed in the Journal of the American Medical Association alleges the risk of adverse gastrointestinal events associated with the use of GLP-1 agonists that are used not only to treat diabetes but also off-label for weight loss

Key Takeaway Weight loss plateaus on semaglutide or tirzepatide are expected, evidence-based, and driven by normal metabolic physiology

For once-weekly GLP-1 medications, follow your medications specific prescribing information.GLP-1s allows changing your injection day if at least 2 days (48 hours) have passed since your last dose

A quality electrolyte supplement designed for GLP-1 users addresses this gap directly

Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide agonists and other metabolic hormones for the treatment of chronic kidney disease

This variability highlights why sourcing options, program eligibility, and clinician guidance are essential for practical affordability